Talphera, Inc. ( (TLPH) ) has released its Q2 earnings. Here is a breakdown of the information Talphera, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Talphera, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative therapies for use in medically supervised settings, with a focus on the anticoagulant nafamostat.
In its latest financial report for the second quarter of 2025, Talphera highlighted significant progress in its NEPHRO clinical study, which is on track for completion by the end of the year. The company also reported a cash balance of $6.8 million as of June 30, 2025.
Key financial metrics revealed a net loss of $3.5 million for the quarter, a slight improvement from the previous year’s loss of $3.8 million. This reduction was attributed to lower personnel expenses and a decrease in general and administrative costs. Talphera also announced a financing arrangement contingent on patient enrollment milestones, which could provide up to $14.8 million in funding.
The company plans to expand its clinical trial sites to 13 by the end of the third quarter, aiming to accelerate patient enrollment. This expansion is part of Talphera’s strategy to ensure the timely completion of its NEPHRO study and subsequent PMA submission in early 2026.
Looking ahead, Talphera remains focused on advancing its clinical trials and managing expenses, with projected cash operating expenses for 2025 set between $16 million and $17 million. The company is optimistic about the potential of nafamostat to meet unmet needs in anticoagulation therapy.